Member Info for closettrader

I think people here are missing the point. SNG is a broad-spectrum anti-viral therapeutic that alleviates acute LUNG infection and can save many lives. It's principal use is at the BEGINNING of a Covid pandemic, when a new, unknown virus is attacking the lungs, resulting in breathlessness and sometImes, unfortunately, death, when there are no vaccines available and Health services around the world are in panic, such as happened in the first half of 2020 with the original and Delta variant of Covid-19.

The Covid virus has now altered to Omicron, which is far less deadly than the original/Delta variant (S. Korea stated today it is 75% less deadly), it does not attack the lungs, the death rate from Covid in the UK and elsewhere is going down, freedom is being restored and the Health service is not in a panic. SNG should have been given EUA in July 2020 to save many lives but unfortunately it wasn't.

As I said earlier today two questions remain as to the future success of SNG. Firstly, will the PII/PIII ACTIV-2 study in the US include enough patients with severe lung infections for SNG to make a statistically significant difference and therefore be approved by the US for EUA? Secondly, will these results, and those already published, convince enough countries to stockpile SNG as an immediate treatment of the next lung-infecting Covid variant that comes along and that vaccines will, again, take years to combat? This seems to always have been SNG’s background target…..with RM stating in an early ProActive interview that if SNG had been around then Covid-19 may well not have become a pandemic. One thing is for sure though, there will be a new deadly variant of Covid, or another respiratory disease, coming along at some time in the future.....just let's hope that we have stocks of SNG ready for it...............

Discussion about SNG’s effectiveness in the PIII analysis surely has to involve the variant that hospital patients were suffering from……a)Omicron does not affect the lungs b) SNG’s primary use is alleviating viral infections of the lungs

Cont…..
In summary it seems the SNG is brilliant at alleviating problems and reducing deaths where the viral infection has reached the lungs - that was always what it was developed for as a broad-spectrum anti-viral inhaled therapeutic. So, in my mind, two questions remain as to the future success of SNG. Firstly, will the PII/PIII ACTIV-2 study in the US include enough patients with severe lung infections for SNG to make a statistically significant difference and therefore be approved by the US for EUA? Secondly, will these results, and those already published, convince enough countries to stockpile SNG as an immediate treatment of the next lung-infecting Covid variant that comes along and that vaccines will, again, take years to combat? This seems to always have been SNG’s background target…..with RM stating in an early ProActive interview that if SNG had been around then Covid-19 may well not have become a pandemic.

Cont…..
We were all impatient for PIII trials but, amazingly, even though we were still in the middle of this pandemic, it took until January 2021 for them to begin, with unfortunately many deaths occurring over the intervening 7 months. The PIII trial was announced as being for just over 600 patients from 17 countries and was to be run by Parexel Biotech on behalf of SNG. At the time, and has been mentioned here again recently, this seemed far too low a number of patients to give definitive evidence of toleration and effectiveness in what could be one of the most important developments ever in inhaled anti-viral therapies. It is also worth remembering that only 50% of the patients would actually receive the drug (the other 300 receiving the placebo).

And so it turned out……the results released on Manic Monday 2 for the Secondary Endpoints (for severe disease and death) gave an approx. 30% relative risk reduction and P11%.......a larger sample size would very possibly have taken us down to the required P5% and a successful result.

However, it is the complete failure of meeting the Primary Endpoint (speed for discharging from hospital) that was most disappointing. RM stated, ‘SNG001 has been administered to hospitalised patients on top of standard of care which changed substantially between our Phase 2 and Phase 3 trials. This improvement in patient care may have compromised the potential of SNG001 to show a clinical benefit in respect of the endpoints for this study….’.
However, the recruitment of patients for the PIII trial was only completed in November 21 by which time Omicron had become the dominant variant in many countries. Omicron is now recognised as being less likely to lead to severe disease and death (an update today from S. Korea says 75% less likely) and DOES NOT lead to severe lung problems – therefore, by inference, SNG would be less effective in its treatment anyway. So perhaps it was not just the SOC that affected the patients but also the type of variant that the patients were suffering from.

Cont……..

I find when suffering disappointment in a stock I own, especially one with such life-saving potential as SNG, it is worth re-reading previous RNS's to refresh thoughts on the development path that the Company has pursued and where it may be heading in the future – it’s over 3 postings I’m afraid.
I'm sure we all remember the blockbuster SPRINTER PII results from a trial of 101 hospitalised patients in 9 UK hospitals. This was RNS'd in July 2020 from trials run during the start of the pandemic (March - May 2020) when the Delta variant caused huge problems through its ability to infect the lungs, leading to severe breathlessness and sometimes death. SNG was reported as reducing the odds of developing severe disease (requiring ventilation or resulting in death) by 79%, patients were more than twice as likely to recover and the measure of breathlessness was markedly reduced - a phenomenal result! As TW said in the RNS: 'The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus', and from Prof Stephen Holgate (not yet knighted!): 'our inhaled treatment of giving high local concentrations of interferon beta, a naturally occurring antiviral protein, restores the lung’s ability to neutralise the virus, or any mutation of the virus or co-infection with another respiratory virus such as influenza or RSV, as could be encountered in the winter if there is a resurgence of COVID-19.' This RNS understandably led to a 5 fold increase in the share price from 40 to 200.
Now a lot of people, myself included, thought that these results justified an EUA for the UK even though the sample size was relatively small - the treatment was based on a naturally occurring protein that had been used historically in the treatment of MS and was therefore known to be well tolerated and it had now produced amazing results in the hospital treatment of Covid-19. SNG would undoubtedly have saved lives whilst Delta was the dominant variant, but unfortunately the UK Government policy was solely for vaccinations and probably thought that any inclusion of SNG as a successful treatment within that policy would have reduced the take-up of the vaccine.
Cont…….

2 x 100000 trades now showing up from mid afternoon .........confirmation news due soon on Total's Venus drill which sits very close to Eco's licence, along with Shell's recent Graff-1 successful drill

Consistent buying over the last few hours and spread tightening....now 35p to both Buy and Sell

That's 1.4 and 2.0 pence for the incentive shares.....not pounds.....!

Now 6.58 to buy, 6.2 to sell......steady climb over the last few days

Just checked on the London Stock Exchange site and it shows 2 late reported deals last night for £9000 and £8700 (both for 150000 shares) that did not show up on LSE - haven't seen that size trade in a while. After all this time there are still only 138m shares in circulation which is remarkable - currently 6.18 to buy, 6.04 to sell

I'm currently being offered 6.03p for my shares ....not the 5.7p as shown on LSE. £1m placing was done in March '21 at 7.5p and the loan of £3.2m from Polo (plus the extra £300k if GCM elect to take it) can be converted to shares at the same price. A few buys are now coming through and judging by ****stan, China, USA, etc then coal is going to be a significant energy resource for a few years to come yet. GCM's resource would be transformational for Bangladesh.......

Earl lost whatever credibility he had left last week when he tried to encourage PI's to invest in TRP saying its licence is next to Shell's promising Graff-1 drill, offshore Namibia...........when it is actually over 1000km away..........!!

Please stop replying on EarlofAims thread....it just gives credence to his misinformation

All TRP and GBP investors - Please do some research as to the locations of the license block Shell is currently drilling compared to where both TRP and GBP have their licenses .....you will find they are a long way away......

Great fan of the potential of this share…… but shouldn’t Art have disclosed the new info on the prospect rather than sitting on it since Aug 21 (from memory of his podcast)?

Torreagus: It is not at least 12m of oil.

The RNS states: 'an approximate 12 metre gross oil column was encountered. Wireline logging results will be used to determine the reservoir properties (porosity, net to gross) and to confirm a net oil column.'

The net oil column will be less than 12m.......

https://www.hellenicshippingnews.com/viridis-bulk-carriers-granted-public-funding-to-build-ammonia-powered-vessels/

Relevant to us?

Full ask up to £500....nothing available over

…… and there’s a huge difference between saying the patient died WITH omicron compared to the patient died BECAUSE OF omicron…… and all the reports I’ve seen so far say the former …….. hmmmm

Do a dummy sell……. Barx is quoting 5.85…..